Calvin Chao

1.0k total citations
47 papers, 492 citations indexed

About

Calvin Chao is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Calvin Chao has authored 47 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cancer Research, 22 papers in Oncology and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Calvin Chao's work include Breast Cancer Treatment Studies (27 papers), Cancer Genomics and Diagnostics (16 papers) and Genetic factors in colorectal cancer (13 papers). Calvin Chao is often cited by papers focused on Breast Cancer Treatment Studies (27 papers), Cancer Genomics and Diagnostics (16 papers) and Genetic factors in colorectal cancer (13 papers). Calvin Chao collaborates with scholars based in United States, Japan and Canada. Calvin Chao's co-authors include Carl Yoshizawa, G. Bruce Mann, Michael S. Broder, Richard H. De Boer, David Speakman, Benjamin Kim, Margarita Lopatin, Roberto Bugarini, Ruth Oratz and Seigo Nakamura and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Calvin Chao

44 papers receiving 488 citations

Peers

Countries citing papers authored by Calvin Chao

Since Specialization

Citations

This map shows the geographic impact of Calvin Chao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Calvin Chao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Calvin Chao more than expected).

Fields of papers citing papers by Calvin Chao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Calvin Chao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Calvin Chao. The network helps show where Calvin Chao may publish in the future.

Co-authorship network of co-authors of Calvin Chao

This figure shows the co-authorship network connecting the top 25 collaborators of Calvin Chao. A scholar is included among the top collaborators of Calvin Chao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Calvin Chao. Calvin Chao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity 2025 ·Clinical Cancer Research ·Andrew A. Davis, (unknown), Ian S. Hagemann, Amir Behdad, (unknown), Lorenzo Gerratana, Elizabeth Mauer, Ami N. Shah, Paolo D’Amico, Lisa Flaum, Carolina Reduzzi, (unknown), William J. Gradishar, (unknown), Calvin Chao, Massimo Cristofanilli	0
2	ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor–Positive Breast Cancer 2025 ·Clinical Cancer Research ·Chang‐Ching Lin, (unknown), Nisha Unni, (unknown), Yisheng Fang, Lei Guo, Fabiana Napolitano, (unknown), (unknown), Calvin Chao, Lin Xu, Carlos L. Arteaga, Ariella B. Hanker	2
3	Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated Cancers 2025 ·Cancers ·Catherine H. Marshall, (unknown), (unknown), Stamatina Fragkogianni, (unknown), (unknown), Lukasz P. Gondek, Calvin Chao, Jun Luo, Emmanuel S. Antonarakis	0
4	Clinicopathologic and molecular landscape of invasive mucinous adenocarcinoma of the lung. 2024 ·Journal of Clinical Oncology ·(unknown), Adam Dugan, (unknown), Calvin Chao, Young Kwang Chae	0
5	Abstract PO3-23-09: ESR1 mutations drive resistance to CDK4/6 inhibitors in ER+ Breast Cancer 2024 ·Cancer Research ·(unknown), Chang‐Ching Lin, (unknown), (unknown), Lei Guo, (unknown), Fabiana Napolitano, Calvin Chao, Ariella B. Hanker, Carlos L. Arteaga	1
6	Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin 2022 ·Journal of Gastrointestinal Oncology ·Greg Yothers, Alan P. Venook, Eiji Oki, Donna Niedzwiecki, Yan Lin, Michael Crager, Calvin Chao, Frederick L. Baehner, Norman Wolmark, Takayuki Yoshino	2
7	Substantial Reduction in Adjuvant Chemotherapy With the Use of the 21-Gene Test to Manage Early Breast Cancer in a Public Hospital in Brazil 2021 ·JCO Global Oncology ·André Mattar, (unknown), (unknown), (unknown), Vilmar Marques de Oliveira, (unknown), Fábio Bagnoli, (unknown), (unknown), (unknown), (unknown), Calvin Chao, (unknown), Luíz Henrique Gebrim	11
8	Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65 2017 ·Breast Cancer Research ·Suzanne C. O’Neill, Claudine Isaacs, Filipa Lynce, Deena Graham, Calvin Chao, Vanessa B. Sheppard, Yingjun Zhou, Chun‐Fu Liu, Nandini Selvam, Marc D. Schwartz, Arnold L. Potosky	8
9	A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer 2016 ·BMC Cancer ·Rangaswamy Govindarajan, James Posey, Calvin Chao, Ruixiao Lu, Trafina Jadhav, (unknown), Awais Javed, Fade Mahmoud, Raymond U. Osarogiagbon, Upender Manne	12
10	The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong 2016 ·Clinical Breast Cancer ·(unknown), Thomas Yau, Miranda Chan, Sharon Chan, (unknown), (unknown), T Wong, Calvin Chao, Carl Yoshizawa, Inda Soong, (unknown), (unknown), (unknown), Roger K.C. Ngan, Catherine S. K. Cheung	17
11	Prospective evaluation of the impact of the 21-gene recurrence score® assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada 2016 ·Annals of Oncology ·(unknown), Maureen Trudeau, Sonal Gandhi, Ellen Warner, (unknown), Kathleen I. Pritchard, Teresa M. Petrella, Elzbieta Slodkowska, (unknown), Calvin Chao, Andrea Eisen	2
12	PD-012 Validation study of the 12-gene Recurrence Score (RS) in patients (pts) with stage II and III colon cancer (CC) without adjuvant chemotherapy; SUNRISE Study 2015 ·Annals of Oncology ·Masataka Ikeda, Takeharu Yamanaka, Kentaro Yamazaki, Kensei Yamaguchi, Kei Muro, Tamon Kusumoto, Hiroyuki Uetake, Takeo Sato, Takaharu Kato, Tomohiro Nishina, Akiyoshi Kanazawa, Eiji Oki, Calvin Chao, Tara Maddala, (unknown), Kiwamu Akagi, A. Ochiai, Yasuo Ohashi, Atsushi Ohtsu, Takayuki Yoshino	2
13	Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients 2015 ·Value in Health ·Baruch Brenner, Ravit Geva, Megan Rothney, Alexander Beny, (unknown), Mariana Steiner, Ayala Hubert, Efraim Idelevich, (unknown), Ofer Purim, Einat Shacham‐Shmueli, Katerina Shulman, Moshe Mishaeli, (unknown), Lior Soussan‐Gutman, (unknown), Calvin Chao, Adi Shani, Nicky Liebermann	13
14	Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years 2015 ·Journal of the National Comprehensive Cancer Network ·Suzanne C. O’Neill, Claudine Isaacs, Calvin Chao, Huei‐Ting Tsai, Chun‐Fu Liu, (unknown), Nandini Selvam, Larry G. Kessler, Marc D. Schwartz, Tania Lobo, Arnold L. Potosky	15
15	Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan 2014 ·BMC Health Services Research ·Hideko Yamauchi, (unknown), (unknown), Hiroyuki Takei, Hiroshi Yagata, Atsushi Yoshida, Naoki Hayashi, John Hornberger, Tiffany M. Yu, Calvin Chao, Carl Yoshizawa, Seigo Nakamura	18
16	Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer 2013 ·Clinical Cancer Research ·Vered Stearns, Lisa K. Jacobs, (unknown), Theodore N. Tsangaris, Michelle A. Rudek, Michaela J. Higgins, Julie R. Lange, (unknown), Shannon A. Slater, Stacie C. Jeter, Penny Powers, Susanne Briest, Calvin Chao, Carl Yoshizawa, Elizabeth A. Sugar, Igor Espinoza‐Delgado, Saraswati Sukumar, Edward Gabrielson, Nancy E. Davidson	24
17	Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer 2013 ·Clinical Breast Cancer ·Hideko Yamauchi, (unknown), Hiroyuki Takei, Calvin Chao, Carl Yoshizawa, Hiroshi Yagata, Atsushi Yoshida, Naoki Hayashi, (unknown), Seigo Nakamura	38
18	A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer 2013 ·European Journal of Cancer ·(unknown), (unknown), Susan Ellard, Caroline Lohrisch, Karen A. Gelmon, Tamara Shenkier, Diego Villa, Howard J. Lim, Sophie Sun, Sara Taylor, Morag Taylor, (unknown), Malcolm Hayes, Diana Beşliu-Ionescu, Carl Yoshizawa, Calvin Chao, Stuart Peacock, Stephen Chia	44
19	The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer 2013 ·The Medical Journal of Australia ·Richard H. De Boer, (unknown), David Speakman, Calvin Chao, Carl Yoshizawa, G. Bruce Mann	56
20	A Study of the Impact of the 21-Gene Breast Cancer Assay on the Use of Adjuvant Chemotherapy in Women With Breast Cancer in a Mexican Public Hospital 2012 ·Annals of Oncology ·Enrique Bargalló‐Rocha, (unknown), (unknown), Víctor M. Pérez-Sánchez, Cynthia Villarreal‐Garza, Héctor Aquiles Maldonado-Martínez, Alejandro Mohar, (unknown), Emily Burke, Calvin Chao	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact